Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.50 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938658 | 0.92 | EGFR (0.56) | EGFRMAP3K8FGFR1 | |
| SCHEMBL12944770 | 0.86 | SIGMAR1 (0.42) | EGFRKDRSIGMAR1METPRKCQ | |
| SCHEMBL12944773 | 0.84 | EGFR (0.47) | EGFRKDRSIGMAR1METPRKCQ | |
| SCHEMBL938318 | 0.83 | STK3 (0.52) | EGFRSRCKDRMET | |
| SCHEMBL938837 | 0.82 | EGFR (0.57) | EGFR | |
| SCHEMBL938557 | 0.79 | KDR (0.65) | EGFRKDRMETTNNI3KFGFR1 | |
| SCHEMBL938524 | 0.78 | EGFR (0.67) | EGFRSRCMAP3K8PRKCQ | |
| SCHEMBL12945022 | 0.75 | EGFR (0.48) | EGFR | |
| SCHEMBL12908994 | 0.75 | EGFR (0.49) | EGFRMAP3K8PRKCQ | |
| SCHEMBL937872 | 0.74 | EGFR (0.62) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524722-B2 | Substituted tricyclic compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| US-8524722-B2 | Substituted tricyclic compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2212332-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| EP-2212332-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2212332-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009033581-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009033581-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, CYP11B1, CYP11A1 | EGFR 1771/4885SRC 1578/4885KDR 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.